Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer

Prostate

Volumn 70, Issue 1, 2010, Pages 70-78

  Salagierski, Maciej ^a,b   Verhaegh, Gerald W ^a,c   Jannink, Sander A ^d   Smit, Frank P ^d   Hessels, Daphne ^d   Schalken, Jack A ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NovioGendix   (Netherlands)

Author keywords

Diagnosis; Gene regulation; PCA3; Prostate cancer; PRUNE2(BMCC1)

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ISOPROTEIN; PROTEIN PCA3; PROTEIN PRUNE2; RNA DIRECTED DNA POLYMERASE; TRANSCRIPTION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE STRUCTURE; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; RNA ISOLATION;

AGED; ANTIGENS, NEOPLASM; CARRIER PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, OVERLAPPING; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 72849126582     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21040     Document Type: Article

References (17)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Chodak G. Prostate cancer: Epidemiology, screening, and biomarkers. Rev Urol 2006;8(Suppl 2):S3-S8.
3. Roobol MJ, Zappa M, Maattanen L, Ciatto S. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC). Prostate 2007;67:439-446. (Pubitemid 46341086)
4. Parekh DJ, Ankerst DP, Troyer D, Srivastava S, Thompson IM. Biomarkers for prostate cancer detection. J Urol 2007;178:2252-2259.
5. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-5979. (Pubitemid 30004960)
6. Schostak M, Schwall GP, Poznanovic S, Groebe K, Muller M, Messinger D, Miller K, Krause H, Pelzer A, Horninger W, Klocker H, Hennenlotter J, Feyerabend S, Stenzl A, Schrattenholz A. Annexin A3 in urine: Ahighly specific noninvasive marker for prostate cancer early detection. J Urol 2009;181:343-353.
7. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007;13:5103-5108. (Pubitemid 47502077)
8. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457:910-914.
9. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15.
10. Verhaegh GW, van Bokhoven A, Smit F, Schalken JA, Busse-makers MJ. Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene. J Biol Chem 2000; 275:37496-37503. (Pubitemid 32004857)
11. Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: Differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology 2003;62:34-43. (Pubitemid 37371888)
12. Clarke RA, Zhao Z, Guo AY, Roper K, Teng L, Fang ZM, Samaratunga H, Lavin MF, Gardiner RA. New genomic structure for prostate cancer specific gene PCA3 within BMCC1: Implications for prostate cancer detection and progression. PLoS One 2009;4:e4995.
13. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:e45.
14. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW, Span PN. Normalization of gene expression measurements in tumor tissues: Comparison of 13 endogenous control genes. Lab Invest 2005;85:154-159. (Pubitemid 40128049)
15. van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, Witjes JA, Jansen CF, Mulders PF, Rittenhouse HG, Schalken JA. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008;68: 1215-1222.
16. Machida T, Fujita T, Ooo ML, Ohira M, Isogai E, Mihara M, Hirato J, Tomotsune D, Hirata T, Fujimori M, Adachi W, Nakagawara A. Increased expression of proapoptotic BMCC1, a novel gene with the BNIP2 and Cdc42GAP homology (BCH) domain, is associated with favorable prognosis in human neuroblastomas. Oncogene 2006;25:1931-1942.
17. Soh UJ, Low BC. BNIP2 extra long inhibits RhoA and cellular transformation by Lbc RhoGEF via its BCH domain. J Cell Sci 2008;121:1739-1749.